Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Eisenstadt – page 27

861 clinical trials in Eisenstadt, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Eisenstadt at a glance
861
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

861 trials in Eisenstadt

Open in trial search

Study on Vinblastine for Children and Adolescents with Standard Risk ALK-Positive Anaplastic Large Cell Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Vinblastine Sulfate
  • Sponsor:GPOH gGmbH

Pre-eclampsia

Recruiting

Study on Aspirin for Preventing Preeclampsia in Twin Pregnancies

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Ewing's sarcoma

Recruiting

Study on Ewing Sarcoma Treatment with Vinorelbine and Drug Combination for Patients with Primary and Disseminated Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:GPOH gGmbH

Study of ONC201 for Patients with Newly Diagnosed H3 K27M-mutant Diffuse Glioma After Radiotherapy

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dordaviprone
  • Sponsor:Chimerix Inc.

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Marstacimab
  • Sponsor:Pfizer Inc.

Pneumonia

Recruiting

Study of Trimodulin for Adults Hospitalized with Severe Community-Acquired Pneumonia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Study on Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Study on Fazirsiran for Patients with Alpha-1 Antitrypsin Deficiency-Related Liver Disease and Fibrosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fazirsiran
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Effects of XEN1101 and Placebo for Patients with Primary Generalized Tonic-Clonic Seizures

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on Desflurane, Sevoflurane, and Propofol for Postoperative Delirium in Elderly Patients Undergoing Major Abdominal Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Desflurane
  • Sponsor:Medical University Of Vienna

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Eisenstadt

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure and pulmonary hypertension, specifically addressing conditions related to left heart disease. These trials aim to evaluate new therapeutic approaches for patients with complex cardiovascular conditions.

  • Heart Failure Management
  • Pulmonary Vascular Disease
  • Left Heart Disease Complications

The research examines treatment effectiveness in patients with WHO Group 2 pulmonary hypertension, exploring potential improvements in pulmonary vascular resistance over a 24-week period.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.